Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 9, 2007, Pages 666-675

  Scholz, Eberhard P ^a   Zitron, Edgar ^a   Kiesecker, Claudia ^a   Thomas, Dierk ^a   Kathöfer, Sven ^a   Kreuzer, Jörg ^b   Bauer, Alexander ^a   Katus, Hugo A ^a   Remppis, Andrew ^a   Karle, Christoph A ^a   Greten, Johannes ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b St Vincenz Hospital   (Germany)

^c German Society of Traditional Chinese Medicine   (Germany)

Author keywords

Arrhythmia; Flavonoids; hERG; Hesperetin; Potassium channel; Repolarisation

Indexed keywords

AROMATIC AMINO ACID; HESPERETIN; HESPERIDIN; KCNH2 PROTEIN, HUMAN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CARDIOVASCULAR DISEASE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; OOCYTE; PATCH CLAMP; PHYSIOLOGY; SWEET ORANGE; XENOPUS;

AMINO ACIDS, AROMATIC; ANIMALS; CARDIOVASCULAR DISEASES; CITRUS SINENSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HESPERIDIN; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; XENOPUS;

CITRUS;

EID: 35348862332     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.06.002     Document Type: Article

References (30)

1. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000) 673-751
2. Erlund I., Meririnne E., Alfthan G., and Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131 2 (2001) 235-241
3. Knekt P., Jarvinen R., Reunanen A., and Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 312 (1996) 478-481
4. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., and Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 342 (1993) 1007-1011
5. Geleijnse J.M., Launer L.J., Van der Kuip D.A.M., Hofmann A., and Wittemann J.C.M. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam study. Am J Clin Nutr 75 (2002) 880-886
6. Yochum L., Kushi L.H., Meyer K., and Folsom A.R. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol 149 (1999) 943-949
7. Rimm E.B., Katan M.B., Ascheiro A., Stampfer M.J., and Willet W.C. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 125 (1996) 384-389
8. Ambra R., Rimbach G., dePascual T., Fuchs D., Wenzel U., Daniel H., et al. Genistein affects the expression of genes involved in blood pressure regulation and angiogenesis in primary human endothelial cells. Nutr Metab Cardiovasc Dis 16 (2006) 35-43 10.1016/jnumecd.2005.03.003
9. Mukamal K.J., Maclure M., Muller J.E., Sherwood J.B., and Mittleman M.A. Tea consumption and mortality after acute myocardial infarction. Circulation 105 (2002) 2476-2481
10. Singh B.N., and Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J 109 (1985) 421-430 10.1016/0002-8703(85)90629-5
11. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT-syndrome. Cell 80 (1995) 795-803
12. Sanguinetti M.C., and Jurkiewicz N.K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhthmic agents. J Gen Physiol 96 1 (1990) 195-215
13. Trudeau M.C., Warmke J.W., Ganetzky Y.B., and Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 (1995) 92-95
14. Zitron E., Scholz E., Owen R.W., Luck S., Kiesecker C., Thomas D., et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 111 7 (2005) 835-838
15. Scholz E.P., Zitron E., Kiesecker C., Lueck S., Kathöfer S., Thomas D., et al. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 404-414
16. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97 22 (2000) 12329-12333
17. Scholz E.P., Zitron E., Kiesecker C., Luck S., Thomas D., Kathofer S., et al. Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch Pharmacol 371 6 (2005) 516-525
18. Fernandez D., Ghanta A., Kauffman G., and Sanguinetti M. Physicochemical features of the HERG channel drug binding site. J Biol Chem 279 (2004) 10120-10127
19. Pearlstein R.A., Vaz R.J., Kang J., Chen X.L., Preobrazhenskaya M., Shchekotikhin A.E., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modelling approaches. Bioorg Med Chem Lett 13 (2003) 1829-1835 10.1016/S0960-894X(03)00196-3
20. Ho P.C., Saville D.J., and Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Sci 4 3 (2001) 217-227
21. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 (2003) 32-45 10.1016/S0008-6363(02)00846-5
22. Nielsen I.L.F., Chee W.S.S., Poulsen L., Offord-Cavin E., Rasmussen S.A., Frederiksen H., et al. Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover-trial. J Nutr 136 2 (2006) 404-408
23. Doostdar H., Burke M.D., and Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome p450 cyp1a1 and cyp1b1. Toxicology 144 1-3 (2000) 31-38 10.1016/S0300-483X(99)00215-2
24. Breinholt V.M., Offord E.A., Brouwer C., Nielsen S.E., Brosen K., and Friedberg T. In vitro investigation of cytochrome p450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 40 5 (2002) 609-616 10.1016/S0278-6915(01)00125-9
25. Silbergerg M., Morand C., Mathevon T., Besson C., Manach C., Scalbert A., et al. The bioavailability of polyphenols is highly governed by the capacity of the intestine and the liver to secrete conjugated metabolites. Eur J Nutr 45 2 (2006) 88-96
26. Roden D.M. Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. Cardiovasc Res 67 (2005) 419-425 10.1016/j.cardiores.2005.04.022
27. Roden D.M., and Viswanathan P.C. Genetics of acquired long QT syndrome. J Clin Invest 115 (2005) 2025-2032
28. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
29. Roden D.M., Balser J.R., George A.L., and Anderson M.E. Cardiac ion channels. Annu Rev Physiol 64 (2002) 431-475
30. Kiehn J., Thomas D., Karle C.A., Schöls W., and Kübler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 359 (1999) 212-219